Suppr超能文献

骨肉瘤患者的生存分析:15年经验

Survival analysis of osteosarcoma patients: A 15-year experience.

作者信息

Yasin Nor Faissal, Abdul Rashid Muhammad Lutfi, Ajit Singh Vivek

机构信息

National Orthopaedic Centre of Excellence in Research & Learning (NOCERAL), Department of Orthopaedic Surgery, Faculty of Medicine, University Malaya Medical Centre, University Malaya, Kuala Lumpur, Malaysia.

出版信息

J Orthop Surg (Hong Kong). 2020 Jan-Apr;28(1):2309499019896662. doi: 10.1177/2309499019896662.

Abstract

INTRODUCTION

Management of osteosarcoma has evolved considerably for the past two decades and there have been changes of practices especially pertaining to chemotherapy regime. This is a review of our cases in the past 15 years.

METHOD

This is a retrospective survival analysis study of 128 patients treated at University Malaya Medical Centre (UMMC) from 1997 to 2011.

RESULTS

There were 80 (62.5%) male and 48 (37.5%) female patients with the median age being 15 (5-59). Majority had osteosarcoma of extremities (94.5%). More than 60% patients developed metastasis throughout the course of treatment with 39% presenting with lung metastasis. Osteoblastic osteosarcoma was the commonest subtype (65.6%). Of the 109 patients treated surgically, 84 patients (65.6%) underwent limb salvage surgery while the rest underwent amputation. Seventy-one per cent of patients completed treatment with local recurrence rate of 22.7%. The 5-year and 10-year survival rates were 56.31% (95% CI: 46.20, 65.24) and 22.33% (95% CI: 14.86, 30.76), respectively. The 5-year event-free survival was 52.94% (95% CI: 41.83, 62.87). In multivariate analysis, the independent prognostic factors were presence of metastasis and completion of treatment for both 5-year and 10-year overall survival. Good histological response was only significant for multivariate analysis at 5 years. Patients with metastasis had a hazard ratio of 20.4 at 5 years and 3.26 at 10 years.

CONCLUSION

Overall survival rate for osteosarcoma patients at our centre was comparably higher than other centres in the region. Two independent risk factors for survival are metastatic status and completion of treatment. A standardized chemotherapy regime is essential for long-term survival.

摘要

引言

在过去二十年中,骨肉瘤的治疗方法有了很大的发展,治疗实践发生了变化,尤其是在化疗方案方面。这是对我们过去15年病例的回顾。

方法

这是一项对1997年至2011年在马来亚大学医学中心(UMMC)接受治疗的128例患者进行的回顾性生存分析研究。

结果

有80例(62.5%)男性和48例(37.5%)女性患者,中位年龄为15岁(5 - 59岁)。大多数患者患有四肢骨肉瘤(94.5%)。超过60%的患者在整个治疗过程中发生转移,39%的患者出现肺转移。成骨细胞型骨肉瘤是最常见的亚型(65.6%)。在109例接受手术治疗的患者中,84例(65.6%)接受了保肢手术,其余患者接受了截肢手术。71%的患者完成了治疗,局部复发率为22.7%。5年和10年生存率分别为56.31%(95%可信区间:46.20,65.24)和22.33%(95%可信区间:14.86,30.76)。5年无事件生存率为52.94%(95%可信区间:41.83,62.87)。在多变量分析中,独立的预后因素是转移的存在和5年及10年总生存的治疗完成情况。良好的组织学反应仅在5年的多变量分析中具有显著性。发生转移的患者在5年时的风险比为20.4,在10年时为3.26。

结论

我们中心骨肉瘤患者的总体生存率高于该地区的其他中心。生存的两个独立危险因素是转移状态和治疗完成情况。标准化的化疗方案对长期生存至关重要。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验